JONATHAN S. BLEEKER
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- Luverne, MN
- NPI
- 1457573974
- Received
- $11,484 in 8 records, 2019 to 2025 ($93 general, $11,390 research)
- As principal investigator
- $1,000,262 of research payments to others in 75 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 2 | $50 |
| 2023 | General payment | 1 | $19 |
| 2021 | General payment | 1 | $11 |
| 2021 | Research payment | 1 | $5 |
| 2020 | Research payment | 1 | $3,111 |
| 2019 | General payment | 1 | $11 |
| 2019 | Research payment | 1 | $8,274 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 3 | $11,390 | 2019–2021 |
| PFIZER INC. | 2 | $37 | 2019–2025 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 | 2025 |
| Merck Sharp & Dohme LLC | 1 | $19 | 2023 |
| Gilead Sciences, Inc. | 1 | $11 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3 | $11,390 |
| Education | 4 | $69 |
| Food and Beverage | 1 | $24 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-07-28 | PFIZER INC. | $26 | Education | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-05-07 | E.R. Squibb & Sons, L.L.C. | $24 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2023-06-05 | Merck Sharp & Dohme LLC | $19 | Education | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2021-06-01 | Gilead Sciences, Inc. | $11 | Education | In-kind items and services | 2021 | ||
| 2021-05-26 | Eli Lilly and Company | $5 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2021 | |
| 2020-07-21 | Eli Lilly and Company | $3,111 | Research payment | Cash or cash equivalent | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2020 | |
| 2019-02-12 | PFIZER INC. | $11 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2019 | |
| 2019-01-15 | Eli Lilly and Company | $8,274 | Research payment | Cash or cash equivalent | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center | $5,093 | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of P | 2025 |
| 2025-02-12 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $1,000 | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2025 |
| 2024-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center | $184,943 | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center | $179,448 | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 | 2024 |
| 2024-06-05 | E.R. Squibb & Sons, L.L.C. | Western University Review Board (wirb) | $714 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of | 2024 |
| 2024-03-13 | E.R. Squibb & Sons, L.L.C. | WCG IRB | $1,777 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of | 2024 |
| 2024-01-12 | E.R. Squibb & Sons, L.L.C. | Sanford Research | $11,443 | Phase III MSS 3L CRC Rela+Nivo vs. regorafenib/TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Ni | 2024 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $0 | A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center | $126,695 | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with | 2023 |
| 2023-05-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $4,000 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2023 |
| 2023-02-08 | E.R. Squibb & Sons, L.L.C. | Sanford Research | $39,736 | Phase III MSS 3L CRC Rela+Nivo vs. regorafenib/TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Ni | 2023 |
| 2023-02-02 | E.R. Squibb & Sons, L.L.C. | Sanford Research | $1,464 | Phase II/III 1L MSS CRC Nivo+ SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care | 2023 |
| 2023-01-09 | E.R. Squibb & Sons, L.L.C. | WCG IRB | $3,380 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of | 2023 |
| 2022-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $4,701 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $2,201 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2022 |
| 2022-11-02 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $4,000 | A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Flourouracil in Subjects wi | 2022 |
| 2022-09-26 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $2,500 | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2022 |
| 2022-09-09 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $2,100 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2022 |
| 2022-04-29 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $2,500 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2022 |
| 2022-02-25 | Eli Lilly and Company | SANFORD RESEARCH USD | $17,402 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2022 |
| 2021-12-31 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $1,833 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2021 |
| 2021-09-08 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $275 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2021 |
| 2021-08-04 | Merck Sharp & Dohme LLC | Sanford Cancer Center | $500 | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2021 |
| 2021-02-23 | Eli Lilly and Company | SANFORD RESEARCH USD | $3,210 | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2021 |
| 2021-01-12 | Eli Lilly and Company | SANFORD RESEARCH USD | $2,990 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2021 |
| 2021-01-04 | E.R. Squibb & Sons, L.L.C. | Sanford Research | $66,293 | Phase II III 1L MSS CRC Nivo SOC vs SOC | 2021 |
| 2020-12-08 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $20 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $200 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2020 |
| 2020-09-11 | E.R. Squibb & Sons, L.L.C. | Sanford Research | $11,032 | Phase II III 1L CRC Nivo CT w pt segmentation rational combos | 2020 |
| 2020-08-11 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $1,500 | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2020 |
| 2020-07-27 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $150 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-07-27 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $50 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-06-30 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $500 | A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca | 2020 |
| 2020-06-30 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $1,000 | A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca | 2020 |
| 2020-06-24 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $1,000 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $20 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-06-04 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $2,500 | A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca | 2020 |
| 2020-05-15 | Eli Lilly and Company | SANFORD RESEARCH USD | $6 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2020 |
| 2020-04-21 | Merck Sharp & Dohme LLC | Sanford Cancer Center Oncology Clinic | $1,500 | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2020 |
| 2020-03-05 | Eli Lilly and Company | SANFORD USD MEDICAL CENTER | $239 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2020 |
| 2020-02-28 | PFIZER INC. | Sanford Research | $1,123 | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-02-01 | PFIZER INC. | Sanford Research | $479 | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-01-21 | Eli Lilly and Company | SANFORD RESEARCH USD | $35,031 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2020 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | SANFORD RESEARCH USD | $80 | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | SANFORD INTERNAL MEDICINE BROADWAY | $11 | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $2 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-19 | Merck Sharp & Dohme LLC | SANFORD RESEARCH USD | $12,000 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $5 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $47 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $20 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $42 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $62 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $68 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $2 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $70 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-05-10 | PFIZER INC. | Sanford Research | $2,555 | METASTATIC RENAL CELL CANCER REIGSTRY MARCC REGISTRY | 2019 |
| 2019-05-08 | Eli Lilly and Company | SANFORD RESEARCH USD | $460 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2019 |
| 2019-04-30 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUX FALLS SD | $17 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
| 2019-04-16 | Eli Lilly and Company | SANFORD RESEARCH USD | $154,537 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2019 |
| 2019-04-04 | Merck Sharp & Dohme LLC | SANFORD CANCER CENTER ONCOLOGY CLINIC AND PHARMACY | $350 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2019 |
| 2019-04-03 | E.R. Squibb & Sons, L.L.C. | Sanford Research | $77,242 | Phase II III 1L CRC Nivo CT w pt segmentation rational combos | 2019 |
| 2019-03-28 | AstraZeneca Pharmaceuticals LP | SANFORD RESEARCH USD | $3,416 | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2019 |
| 2019-03-28 | AstraZeneca Pharmaceuticals LP | SANFORD INTERNAL MEDICINE BROADWAY | $500 | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2019 |
| 2019-02-27 | Eli Lilly and Company | Sanford Clinic | $54 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2019 |
| 2019-01-28 | Eli Lilly and Company | SANFORD USD MEDICAL CENTER | $871 | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2019 |
| 2019-01-17 | Merck Sharp & Dohme LLC | SANFORD CANCER CENTER ONCOLOGY CLINIC AND PHARMACY | $350 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2019 |
| 2019-01-17 | Merck Sharp & Dohme LLC | SANFORD CANCER CENTER ONCOLOGY CLINIC AND PHARMACY | $1,040 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2019 |
| 2019-01-11 | Incyte Corporation | Sanford Research | $500 | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 |
| 2019-01-04 | Incyte Corporation | Sanford Research | $203 | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 |
| 2019-01-04 | Incyte Corporation | Sanford Research | $250 | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 |
| 2019-01-04 | Incyte Corporation | Sanford Research | $350 | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 |
| 2019-01-04 | Incyte Corporation | Sanford Research | $1,000 | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 |
| 2019-01-04 | Incyte Corporation | Sanford Research | $1,000 | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 |
| 2019-01-04 | Incyte Corporation | Sanford Research | $350 | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 |
| 2019-01-02 | Merck Sharp & Dohme LLC | SANFORD HEMATOLOGY ONCOLOGY SIOUXFALLS SD | $16,246 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Luverne, MN, county Rock County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Luverne, MN | County Rock County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 4,925 | 9,621 | 5,739,445 |
| Population, 2020 census P1 | 4,946 | 9,704 | 5,706,494 |
| Median age B01002 | 41.3 | 41.2 | 38.8 |
| Under 18 B01001 | 22.7% | 24.4% | 22.9% |
| 65 and over B01001 | 23.2% | 20.4% | 17.3% |
| Households B11001 | 2,196 | 4,035 | 2,307,955 |
| Foreign born B05002 | 1.7% | 1.8% | 8.7% |
| Median household income B19013 | $64,366 | $71,295 | $89,062 |
| Median family income B19113 | $100,779 | $100,605 | $113,993 |
| Per capita income B19301 | $37,079 | $38,826 | $48,237 |
| Poverty rate B17001 | 12.2% | 10.6% | 9.3% |
| Unemployment rate B23025 | 2.5% | 2.6% | 4.1% |
| Civilian labor force B23025 | 2,631 | 5,213 | 3,119,042 |
| Mean commute (minutes) B08013 | 16.0 | 19.6 | 22.7 |
| Bachelor's degree or higher B15003 | 29.2% | 26.3% | 39.4% |
| Housing units B25001 | 2,285 | 4,256 | 2,545,030 |
| Owner-occupied B25003 | 70.8% | 76.6% | 72.2% |
| Renters B25003 | 29.2% | 23.4% | 27.8% |
| Median home value B25077 | $208,000 | $224,300 | $329,300 |
| Median gross rent B25064 | $639 | $698 | $1,280 |
| White, not Hispanic B03002 | 93.4% | 91.4% | 75.9% |
| Black B03002 | 0.0% | 0.1% | 6.9% |
| Hispanic or Latino B03002 | 2.5% | 4.0% | 6.4% |
| Asian B03002 | 0.4% | 0.4% | 5.1% |
| American Indian and Alaska Native B03002 | 0.2% | 0.5% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Luverne, MN.
Comments